These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 23859802)
1. Development of boceprevir: a first-in-class direct antiviral treatment for chronic hepatitis C infection. Hazuda DJ; Burroughs M; Howe AY; Wahl J; Venkatraman S Ann N Y Acad Sci; 2013 Jul; 1291():69-76. PubMed ID: 23859802 [TBL] [Abstract][Full Text] [Related]
2. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections. Venkatraman S Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415 [TBL] [Abstract][Full Text] [Related]
3. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C. Chen KX; Njoroge FG Prog Med Chem; 2010; 49():1-36. PubMed ID: 20855037 [No Abstract] [Full Text] [Related]
4. Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection. Trembling PM; Tanwar S; Dusheiko GM Expert Rev Anti Infect Ther; 2012 Mar; 10(3):269-79. PubMed ID: 22397560 [TBL] [Abstract][Full Text] [Related]
6. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Njoroge FG; Chen KX; Shih NY; Piwinski JJ Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821 [TBL] [Abstract][Full Text] [Related]
7. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. Silva MO; Treitel M; Graham DJ; Curry S; Frontera MJ; McMonagle P; Gupta S; Hughes E; Chase R; Lahser F; Barnard RJ; Howe AY; Howe JA J Hepatol; 2013 Jul; 59(1):31-7. PubMed ID: 23454058 [TBL] [Abstract][Full Text] [Related]
8. New developments in HCV therapy. Kronenberger B; Zeuzem S J Viral Hepat; 2012 Jan; 19 Suppl 1():48-51. PubMed ID: 22233414 [TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus resistance to protease inhibitors. Halfon P; Locarnini S J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949 [TBL] [Abstract][Full Text] [Related]
10. The discovery and development of boceprevir. Rotella DP Expert Opin Drug Discov; 2013 Nov; 8(11):1439-47. PubMed ID: 24079543 [TBL] [Abstract][Full Text] [Related]
11. Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Klibanov OM; Vickery SB; Olin JL; Smith LS; Williams SH Pharmacotherapy; 2012 Feb; 32(2):173-90. PubMed ID: 22392426 [TBL] [Abstract][Full Text] [Related]
12. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Welsch C; Jesudian A; Zeuzem S; Jacobson I Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918 [TBL] [Abstract][Full Text] [Related]
13. Future of hepatitis C therapy: development of direct-acting antivirals. Dore GJ; Matthews GV; Rockstroh J Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228 [TBL] [Abstract][Full Text] [Related]
14. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver]. Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z; Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266 [TBL] [Abstract][Full Text] [Related]